Journal of Microbiology and Biotechnology

  • 제17권4호
  • /
  • Pages.611-615
  • /
  • 2007
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지

Immunogenicity and Safety of Vi Capsular Polysaccharide Typhoid Vaccine in Healthy Persons in Korea

  • Lim, Sang-Min (Central Research Institute, Boryung Pharm, Co., Ltd.) ;
  • Jung, Hahn-Sun (Central Research Institute, Boryung Pharm, Co., Ltd.) ;
  • Kim, Min-Ja (Department of Internal Medicine Korea University, College of Medicine) ;
  • Park, Dae-Won (Department of Internal Medicine Korea University, College of Medicine) ;
  • Kim, Woo-Joo (Department of Internal Medicine Korea University, College of Medicine) ;
  • Cheong, Hee-Jin (Department of Internal Medicine Korea University, College of Medicine) ;
  • Park, Seung-Chul (Department of Internal Medicine Korea University, College of Medicine) ;
  • Lee, Kwang-Chul (Department of Pediatrics, Korea University, College of Medicine) ;
  • Shin, Young-Kyoo (Department of Pediatrics, Korea University, College of Medicine) ;
  • Tan, Hyun-Kwang (Central Research Institute, Boryung Pharm, Co., Ltd.) ;
  • Kim, Sang-Lin (Central Research Institute, Boryung Pharm, Co., Ltd.) ;
  • Sohn, Jang-Wook (Department of Internal Medicine Korea University, College of Medicine)
  • 발행 : 2007.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were $5.87{\pm}1.34\;and\;142.59{\pm}2.39$ at one month after vaccination. For adults, the GMTs before and one month after vaccination were $5.58{\pm}1.28\;and\;58.56{\pm}3.67$, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.

키워드

참고문헌

  1. Acharya, I. L., C. U. Lowe, R. Thapa, V. L. Gurubacharya, M. B. Shrestha, M. Cadoz, D. Schulz, J. Armand, D. A. Bryla, B. Trollfors, T. Cramton, R. Schneerson, and J. B. Robbins. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report. N. Engl. J. Med. 317: 1101-1104 https://doi.org/10.1056/NEJM198710293171801
  2. Ackers, M. L., N. D. Puhr, R. V. Tauxe, and E. D. Mintz. 2000. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: Antimicrobial resistance on the rise. JAMA 283: 2668
  3. Beiger, E. M., D. R. Burwen, P. Haber, and R. Ball. 2004. Postmarketing safety surveillance for typhoid fever vaccines from the vaccine adverse event reporting system, July 1990 through June 2002. Clin. Infect. Dis. 38: 771-779 https://doi.org/10.1086/381548
  4. Bodhidatta, L., D. N. Taylor, U. Thisyakom, and P. Echeverria. 1987. Control of typhoid fever in Bangkok, Thailand, by annual immunization of school children with parenteral typhoid vaccine. Rev. Infect. Dis. 9: 841-845 https://doi.org/10.1093/clinids/9.4.841
  5. Center for Disease Control and Prevention. 1994. Typhoid immunization recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR 43(RR-14): 1-6
  6. Centers for Disease Control and Prevention. High priority potential bioterrorism agents list. Available at http://www.bt.cdc.gov/Agent/agentlist.asp. Accessed 12 January 2004
  7. Engels, E. A., M. E. Falagas, J. Lau, and M. L. Bennish. 1998. Typhoid fever vaccines: A meta-analysis of studies on efficacy and toxicity. BMJ 316: 110-116 https://doi.org/10.1136/bmj.316.7125.110
  8. Joo, J. H. and J. W. Yun. 2005. Structural and molecular characterization of extracellular polysaccharides produced by a new fungal strain, Trichoderma erinaceum DG-312. J. Microbiol. Biotechnol. 15: 1250-1257
  9. Keddy, K. H., K. P. Klugman, C. F. Hansford, C. Blonde, and N. B. Nancy. 1999. Persistence of antibodies to the Salmonella typhi, Vi capsular polysacchride vaccine in South African school children 10 years after immunization. Vaccine 17: 110-113 https://doi.org/10.1016/S0264-410X(98)00160-1
  10. Keitel, W. A., N. L. Bond, J. M. Zahradnik, T. A. Cramton, and J. B. Robbins. 1994. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12: 195-199 https://doi.org/10.1016/0264-410X(94)90194-5
  11. Klugman, K. P., H. J. Koornhof, J. B. Robbins, and N. N. Le Cam. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14: 435-438 https://doi.org/10.1016/0264-410X(95)00186-5
  12. Korea Center for Disease Control and Prevention. Communicable disease information. 2000. Available at http://dis.mohw.go.kr/information/info.asp
  13. Kroon, F. P., J. T. V. Dissel, E. Ravensbergen, P. H. Nibbering, and R. V. Furth. 1999. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-$Vi^{\circledR}$). Vaccine 17: 2941-2945 https://doi.org/10.1016/S0264-410X(99)00167-X
  14. Landy, M. and E. Lamb. 1953. Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc. Soc. Exp. Biol. Med. 82: 593-598
  15. Maskalyk, J. 2003. Typhoid fever. CMAJ 169: 132
  16. Mermin, J. H., R. Villar, J. Carpenter, L. Roberts, A. Samaridden, L. Gasanova, S. Lomakina, C. Bopp, L. Hutwagner, P. Mead, B. Ross, and E. D. Mintz. 1999. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J. Infect. Dis. 179: 1416-1422 https://doi.org/10.1086/314766
  17. Murdoch, D. A., N. A. Banatvala, B. I. Shoismatulloev, L. R. Ward, and E. J. Threlfall. 1988. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351: 339
  18. Murphy, J. R., L. Grez, L. Schlesinger, C. Ferreccio, S. Baqar, C. Munoz, S. S. Wasserman, G. Losonsky, J. G. Olson, and M. M. Levine. 1991. Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect. Immun. 59: 4291-4293
  19. Olsen, S. J., S. C. Bleasdale, A. R. Magnano, C. Landrigan, B. H. Holland, R. V. Tauxe, E. D. Mintz, and S. Luby. 2003. Outbreaks of typhoid fever in the United States, 1960-99. Epidemiol. Infect. 130: 13-21
  20. Panchanathan, V., S. Kumar, W. Yeap, S. Devi, R. Ismail, S. Sarijan, S. M. Sam, Z. Jusoh, S. Nordin, D. Leboulleux, and T. Pang. 2001. Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits. Bull. World Health Organ. 79: 811-817
  21. Park, J. W., W. S. Shin, M. W. Kang, D. K. Ko, and J. H. Kang. 1991. Safety and immunogenicity of the typhoid Vi capsular polysaccharide vaccine. Kor. Soc. Infec. Dis. 23: 145-153
  22. Plotkin, S. A. and N. Bouveret-Le Cam. 1995. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch. Intern. Med. 155: 2293-2299 https://doi.org/10.1001/archinte.155.21.2293
  23. Sabitha, P., M. R. P. Adhikari, A. Chowdary, M. Prabhu, M. Soofi, M. Shetty, A. Kamath, S. S. Lokaranjan, and S. S. Bangera. 2004. Comparison of the immunogenicity and safety of two different brands of Salmonella typhi Vi capsular polysaccharide vaccine. Indian J. Med. Sci. 58: 141-149
  24. Sohn, Y. M., J. H. Kim, and D. B. Gae. 1993. Immunogenicity and safety of the Typhoid Vi capsular polysaccharide vaccine (Typhovax) in children. J. Korean Soc. Chemother. 11: 185-191
  25. Tacket, C. O., C. Ferrecio, J. B. Robbins, C. M. Tsai, D. Schulz, M. Cadoz, A. Goudeau, and M. M. Levine. 1986. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J. Infect. Dis. 154: 342-345 https://doi.org/10.1093/infdis/154.2.342
  26. Tacket, C. O., M. L. Levin, and J. B. Robbins. 1988. Persistance of antibody titers three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine 6: 307-308 https://doi.org/10.1016/0264-410X(88)90175-2
  27. Torok, T. J., R. V. Tauxe, R. P. Wise, J. R. Livengood, R. Sokolow, S. Mauvais, K. A. Birkness, M. R. Skeels, J. M. Horan, and L. R. Foster. 1997. A large community outbreak of salmonellosis caused by intentional contamination cf restaurant salad bars. JAMA 278: 389-395 https://doi.org/10.1001/jama.278.5.389
  28. Wong, K. H., J. C. Feeley, R. S. Northrup, and M. E. Forlines. 1974. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect. Immun. 9: 348-353
  29. Yang, H. H., C. G. Wu, G. Z. Xie, Q. W. Gu, B. R. Wang, L. Y. Wang, H. F. Wang, Z. S. Ding, Y. Yang, W. S. Tar., W. Y. Wang, X. C. Wang, M. Qin, J. H. Wang, H. A. Tang, X. M. Jiang, Y. H. Li, M. L. Wang, S. L. Zhang, and G. L. Li. 2001. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull. World Health Organ. 79: 625-631